Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis

Table 3

Clinical features of patient undergone surgical management with curative intent after radiotherapy and locoregional therapy.

Patient

Age/sex

Etiology

Maximum HCC

PVTT

Treatments

Radiotherapy of PVTT

Overall Responses

Surgical managements

Outcomes

Duration

Dose (Gy)

Response

1

48 Y/M

HBV

2.0 cm

Left PV (Vp3)

Radiotherapy TACE/RFA

45 days

29

CR

CR

DDLT

123.9 ms

Alive

2

59 Y/M

HCV

4.5 cm

Right PV (Vp3)

Radiotherapy TACE

24 days

6

CR

CR

LDLT

77.5 ms

Death

3

49 Y/F

HBV

2.8 cm

Right PV (Vp2)

Radiotherapy TACE

45 days

20

CR

PR

LDLT

57.2 ms

Alive

4

77 Y/M

HBV

4.7 cm

Left PV (Vp3)

Radiotherapy TACE/UFT

35 days

13

SD

PR

Left hepatectomy

9.8 ms

Death

5

60 Y/M

No

6.0 cm

Right PV (Vp2)

Radiotherapy TACE

45 days

22

PR

SD

Extended right hepatectomy

12.26 ms

Death

6

51 Y/M

HBV

4.4 cm

Left PV (Vp2)

Radiotherapy TACE

45 days

21

CR

CR

DDLT

52.1 ms

Alive

Y: years old; M: male; F: female; HBV: hepatitis B virus; HCV: hepatitis C virus; HCC: hepatocellular carcinoma; PV: portal vein; PVT: portal vein tumor thrombosis; TACE: transcatheter arterial chemoembolization; RFA: radiofrequency ablation; UFT: tegafur & uracil; CR: complete response; PR: partial response; SD: stable disease; PD: progression disease; DDLT: decease donor liver transplantation; LDLT: living donor liver transplantation; ms: months.